

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Details : Icotrokinra is a Protein drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 29, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Icotrokinra is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 29, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Clears Skin in Tough Scalp and Genital Psoriasis Patients
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 09, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Clears Plaque Psoriasis in 75% Of Teens in Daily Pill Trial
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Icotrokinra is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Psoriatic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Meets Primary Endpoint in Ulcerative Colitis Study
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Study Results Suggest Potential to Redefine Treatment Standards in Psoriasis
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 08, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Icotrokinra is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Psoriatic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist Announces Positive Results for Icotrokinra in Phase 3 Plaque Psoriasis
Details : JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Shows JNJ-2113 Maintained Skin Clearance in Moderate-To-Severe Psoriasis
Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 09, 2024
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
